Cancer Diagnostics Market by Technology (Flow Cytometry, Imaging, Immunohistochemistry), Cancer Type (Hematological Cancers, Solid Tumors), End User - Global Forecast 2025-2032
Description
The Cancer Diagnostics Market was valued at USD 33.31 billion in 2024 and is projected to grow to USD 37.02 billion in 2025, with a CAGR of 12.12%, reaching USD 83.23 billion by 2032.
A strategic introduction outlining how converging diagnostic innovations are transforming clinical decision-making and research priorities across oncology care
The diagnostic landscape for oncology is evolving rapidly as molecular insights, imaging advances, and single-cell analytics converge to redefine clinical pathways and research priorities. In recent years, incremental innovations have become compound drivers of change, influencing how clinicians stage disease, select targeted therapies, and monitor minimal residual disease. The introduction of higher-resolution imaging modalities and refined immunoassays has enhanced diagnostic confidence, while molecular approaches have uncovered previously hidden biomarkers that inform personalized treatment.
This introduction frames the strategic importance of diagnostics as both a clinical enabler and a commercial focal point. Stakeholders across hospitals, diagnostic laboratories, ambulatory care settings, and research institutes must now reconcile legacy workflows with emerging platforms such as multiparameter flow cytometry, high-throughput sequencing, and advanced in situ hybridization techniques. The resulting interplay between instrumentation, reagents, informatics, and regulatory pathways shapes investment priorities and operational planning. Throughout the document, emphasis is placed on actionable insight that supports decision-makers in prioritizing technologies, optimizing procurement, and aligning clinical adoption with evidence generation.
How multi-modal integration, rapid laboratory workflows, and evolving clinical paradigms are reshaping oncology diagnostics and care delivery models
Transformative shifts are underway across the cancer diagnostics landscape, driven by technological maturation, shifting clinical paradigms, and evolving payer and regulatory expectations. Imaging platforms continue to advance through improved spatial and temporal resolution, while integrated molecular diagnostics are delivering orthogonal data that change diagnostic confidence and treatment selection. At the same time, laboratory workflows are being reimagined to support rapid turnarounds and multiplexed testing, enabling clinicians to act on comprehensive diagnostic profiles in tighter clinical windows.
Beyond instruments and assays, the most consequential shift is the integration of multi-modal data streams. Combining imaging phenotypes with sequencing-derived tumor profiles and immunohistochemical markers creates new opportunities for predictive modeling and adaptive treatment strategies. This shift places a premium on interoperable informatics, standardized reporting, and cross-disciplinary collaboration. In parallel, attention to tissue-sparing methods and minimally invasive sampling is expanding access to diagnostics across care settings, altering referral patterns and the distribution of testing volumes between hospitals, diagnostic labs, and ambulatory services. Collectively, these dynamics are repositioning diagnostics from a confirmatory role to a central element of personalized oncology pathways.
Implications of 2025 United States tariff changes for oncology diagnostics supply chains, procurement strategies, and supplier localization decisions
The introduction of comprehensive tariff adjustments in the United States beginning in 2025 has created a new layer of strategic complexity for diagnostics supply chains, procurement teams, and technology developers. Higher import costs for specialized instruments, reagents, and consumables underscore the need for resilient sourcing strategies and near-term operational contingency planning. Procurement cycles have become more sensitive to landed costs, which in turn influence vendor selection, contract negotiation tactics, and the prioritization of capital investments.
In addition to immediate cost pressures, tariffs have prompted a reassessment of geographic diversification and local manufacturing feasibility. Diagnostic manufacturers and reagent suppliers are evaluating options ranging from regional production hubs to contract manufacturing arrangements to mitigate exposure to cross-border trade policy volatility. Health systems and laboratories are responding by lengthening sourcing lead times and increasing inventory buffers for critical reagents while simultaneously accelerating validation of alternative suppliers. Over time, these adaptations can alter the competitive landscape by favoring players with robust global supply networks, localized production capacity, or vertically integrated supply chains, while amplifying the value of strategic partnerships that provide supply certainty and predictable service levels.
Segment-driven insights showing distinct technology, cancer type, and end-user priorities that influence adoption pathways and evidence generation needs
Segmentation analysis reveals differentiated implications for adoption, clinical utility, and operational deployment across technology, cancer type, and end-user categories. Within technology, flow cytometry-encompassing both cell sorting and multiparameter flow cytometry-remains indispensable for hematologic evaluations and immune profiling, while advanced imaging modalities such as computed tomography, magnetic resonance imaging, positron emission tomography, and ultrasound provide complementary structural and functional context for solid tumors. Immunohistochemistry techniques, including chromogenic and fluorescent approaches, continue to serve as cornerstone histopathology methods, and in situ hybridization retains an important role for spatially resolved nucleic acid detection. Molecular diagnostics platforms-spanning microarray, PCR, and sequencing-are the engines for genomic interrogation and biomarker discovery, enabling precision treatment selection.
When grouped by cancer type, hematological cancers including leukemia, lymphoma, and multiple myeloma prioritize technologies that deliver single-cell resolution, cytogenetics, and rapid flow-based immunophenotyping. Conversely, solid tumors such as breast, colorectal, lung, and prostate cancers increasingly rely on multi-modality diagnostics that integrate imaging biomarkers with molecular profiles and tissue-based assays to guide localized and systemic therapies. From an end-user perspective, ambulatory care settings and hospitals demand turnkey solutions with rapid reporting and easy integration into electronic records, diagnostic laboratories focus on throughput, standardization, and quality controls, and research institutes-both academic and private-prioritize flexible platforms that support exploratory assays, method development, and mechanistic studies. These segmentation-driven contrasts inform technology roadmaps, service models, and evidence generation strategies for diagnostic stakeholders.
Regional dynamics and adoption pathways revealing how geopolitical, regulatory, and infrastructure factors drive differentiation in diagnostic uptake globally
Regional dynamics shape access, reimbursement frameworks, and adoption timelines for diagnostics technologies. In the Americas, investment in imaging infrastructure and molecular laboratories remains strong, driven by integrated health networks and a focus on precision oncology programs. Payor-driven reimbursement mechanisms and private sector procurement strategies influence the pace at which novel assays move into routine care, and cross-border manufacturing considerations affect supply chain resilience. Europe, the Middle East & Africa exhibits heterogeneous adoption patterns: Western European markets emphasize regulatory compliance, centralized reference testing, and robust laboratory accreditation, while emerging markets in the region weigh cost, scalability, and workforce capacity. Regulatory harmonization efforts in parts of the region may accelerate the adoption of standardized diagnostic workflows, but variability persists across national systems.
Asia-Pacific presents a rapidly evolving landscape where investment in high-throughput sequencing and digital pathology is accelerating, particularly in urban centers with strong research ecosystems. Public health priorities, population-scale screening initiatives, and localized manufacturing investments are key drivers. In many Asia-Pacific markets, expanding access to diagnostic services is catalyzing partnerships between hospitals, private laboratories, and research institutes, which in turn fuels demand for scalable, automated platforms. Across all regions, interoperability, data governance, and local regulatory frameworks remain critical considerations that shape deployment strategies and partnership models.
Competitive dynamics and capability strategies highlighting how integrated solutions, niche innovation, and strategic partnerships determine clinical traction
Competitive dynamics in the oncology diagnostics arena are defined by capability depth, portfolio breadth, and the ability to deliver integrated solutions that span instruments, assays, and data analytics. Leading players that combine robust reagent supply chains with instrument compatibility and scalable informatics architectures are positioned to capture complex clinical and research workflows. At the same time, niche innovators focused on specific modalities-such as ultra-sensitive sequencing, advanced multiplexed imaging, or next-generation flow cytometry-are reshaping value propositions by offering higher-resolution insights or workflow efficiencies that incumbents must respond to.
Strategic collaboration between manufacturers, diagnostic laboratories, and research organizations is increasingly common, enabling co-development of assays, real-world validation studies, and accelerated clinical translation. Service models that include managed testing, remote instrument monitoring, and data interpretation services add differentiation beyond hardware and reagents. Intellectual property around assay chemistries and bioinformatic pipelines continues to be a competitive moat, while agility in regulatory strategy, reimbursement engagement, and field support determines commercial traction. Companies that marry regulatory foresight with scalable manufacturing and strong clinical evidence generation will be best placed to lead adoption across diverse care settings.
Actionable recommendations for executives to align technology strategy, supply resilience, and evidence generation to accelerate clinical adoption and commercial success
Industry leaders should adopt a multi-pronged approach that aligns technological investment with operational resilience and evidence-based commercialization. Prioritize platform interoperability and open informatics standards to facilitate multi-modal data integration across imaging, molecular, and tissue-based assays, thereby enhancing clinical utility and easing adoption barriers. Invest in decentralized validation studies that demonstrate performance in ambulatory care, diagnostic laboratory, and hospital environments, ensuring that deployment models are tailored to the realities of each end-user type. Strengthen supplier diversification and inventory strategies to mitigate risks associated with trade policy shifts and component shortages, and evaluate localized manufacturing or contractual manufacturing partnerships where feasible.
From a commercial perspective, accelerate payer engagement to clarify reimbursement pathways and design outcomes studies that align with value-based payment frameworks. Cultivate collaborative partnerships with academic centers and private research institutes to co-create evidence and drive early adoption through key opinion leader endorsement. Finally, embed lifecycle support offerings-training, remote diagnostics, and data services-into commercial models to enhance customer retention and demonstrate total cost of ownership benefits. These actions will help organizations convert technological capability into sustained clinical and market advantage.
A transparent mixed-methods research approach combining primary clinician interviews, secondary technical validation, and scenario analysis to ensure robust insights
The research approach integrates a mixed-methods framework designed to validate findings across primary and secondary sources while ensuring transparency in analytical assumptions. Primary research included structured interviews with clinical leaders, laboratory directors, and procurement specialists across hospitals, diagnostic laboratories, ambulatory care settings, and academic and private research institutes to capture first‑hand insights on adoption drivers, operational constraints, and evidence needs. These qualitative inputs were triangulated with secondary research covering peer-reviewed literature, regulatory guidance documents, and publicly available technical validations to build a comprehensive understanding of modality-specific performance and use cases.
Analytical processes incorporated technology mapping to align instruments and assays with clinical workflows, segmentation analysis to discern end-user and cancer-type priorities, and scenario planning to assess implications of supply chain disruptions and policy shocks. Wherever possible, findings were cross-checked with multiple independent sources to ensure robustness, and caveats are noted where emerging data remain provisional. The methodology emphasizes reproducibility and clarity, enabling stakeholders to understand the provenance of conclusions and to request access to primary interview inventories or methodological appendices for verification and deeper inquiry.
A concise conclusion emphasizing pragmatic alignment of technological potential, supply resilience, and evidence programs to realize precision oncology benefits
In sum, oncology diagnostics stands at an inflection point where cross-disciplinary technologies and shifting policy environments jointly influence clinical pathways and commercial strategies. The most impactful innovations are those that deliver clinically actionable information while fitting within operational constraints across hospitals, laboratories, and ambulatory facilities. Technology adoption will be accelerated by demonstrable improvements in diagnostic confidence and downstream patient management, supported by rigorous evidence generation and streamlined regulatory engagements.
Stakeholders that prioritize data interoperability, supply chain resilience, and collaborative evidence programs will be best positioned to translate diagnostic innovation into improved patient outcomes and sustainable business models. While trade policy and regional heterogeneity introduce complexity, they also create opportunities for strategic localization and partnership. The conclusion emphasizes pragmatic alignment between technological possibility and implementation reality, encouraging decision-makers to integrate these insights into capital planning, clinical pathway redesign, and research collaborations to realize the promise of precision oncology diagnostics.
Please Note: PDF & Excel + Online Access - 1 Year
A strategic introduction outlining how converging diagnostic innovations are transforming clinical decision-making and research priorities across oncology care
The diagnostic landscape for oncology is evolving rapidly as molecular insights, imaging advances, and single-cell analytics converge to redefine clinical pathways and research priorities. In recent years, incremental innovations have become compound drivers of change, influencing how clinicians stage disease, select targeted therapies, and monitor minimal residual disease. The introduction of higher-resolution imaging modalities and refined immunoassays has enhanced diagnostic confidence, while molecular approaches have uncovered previously hidden biomarkers that inform personalized treatment.
This introduction frames the strategic importance of diagnostics as both a clinical enabler and a commercial focal point. Stakeholders across hospitals, diagnostic laboratories, ambulatory care settings, and research institutes must now reconcile legacy workflows with emerging platforms such as multiparameter flow cytometry, high-throughput sequencing, and advanced in situ hybridization techniques. The resulting interplay between instrumentation, reagents, informatics, and regulatory pathways shapes investment priorities and operational planning. Throughout the document, emphasis is placed on actionable insight that supports decision-makers in prioritizing technologies, optimizing procurement, and aligning clinical adoption with evidence generation.
How multi-modal integration, rapid laboratory workflows, and evolving clinical paradigms are reshaping oncology diagnostics and care delivery models
Transformative shifts are underway across the cancer diagnostics landscape, driven by technological maturation, shifting clinical paradigms, and evolving payer and regulatory expectations. Imaging platforms continue to advance through improved spatial and temporal resolution, while integrated molecular diagnostics are delivering orthogonal data that change diagnostic confidence and treatment selection. At the same time, laboratory workflows are being reimagined to support rapid turnarounds and multiplexed testing, enabling clinicians to act on comprehensive diagnostic profiles in tighter clinical windows.
Beyond instruments and assays, the most consequential shift is the integration of multi-modal data streams. Combining imaging phenotypes with sequencing-derived tumor profiles and immunohistochemical markers creates new opportunities for predictive modeling and adaptive treatment strategies. This shift places a premium on interoperable informatics, standardized reporting, and cross-disciplinary collaboration. In parallel, attention to tissue-sparing methods and minimally invasive sampling is expanding access to diagnostics across care settings, altering referral patterns and the distribution of testing volumes between hospitals, diagnostic labs, and ambulatory services. Collectively, these dynamics are repositioning diagnostics from a confirmatory role to a central element of personalized oncology pathways.
Implications of 2025 United States tariff changes for oncology diagnostics supply chains, procurement strategies, and supplier localization decisions
The introduction of comprehensive tariff adjustments in the United States beginning in 2025 has created a new layer of strategic complexity for diagnostics supply chains, procurement teams, and technology developers. Higher import costs for specialized instruments, reagents, and consumables underscore the need for resilient sourcing strategies and near-term operational contingency planning. Procurement cycles have become more sensitive to landed costs, which in turn influence vendor selection, contract negotiation tactics, and the prioritization of capital investments.
In addition to immediate cost pressures, tariffs have prompted a reassessment of geographic diversification and local manufacturing feasibility. Diagnostic manufacturers and reagent suppliers are evaluating options ranging from regional production hubs to contract manufacturing arrangements to mitigate exposure to cross-border trade policy volatility. Health systems and laboratories are responding by lengthening sourcing lead times and increasing inventory buffers for critical reagents while simultaneously accelerating validation of alternative suppliers. Over time, these adaptations can alter the competitive landscape by favoring players with robust global supply networks, localized production capacity, or vertically integrated supply chains, while amplifying the value of strategic partnerships that provide supply certainty and predictable service levels.
Segment-driven insights showing distinct technology, cancer type, and end-user priorities that influence adoption pathways and evidence generation needs
Segmentation analysis reveals differentiated implications for adoption, clinical utility, and operational deployment across technology, cancer type, and end-user categories. Within technology, flow cytometry-encompassing both cell sorting and multiparameter flow cytometry-remains indispensable for hematologic evaluations and immune profiling, while advanced imaging modalities such as computed tomography, magnetic resonance imaging, positron emission tomography, and ultrasound provide complementary structural and functional context for solid tumors. Immunohistochemistry techniques, including chromogenic and fluorescent approaches, continue to serve as cornerstone histopathology methods, and in situ hybridization retains an important role for spatially resolved nucleic acid detection. Molecular diagnostics platforms-spanning microarray, PCR, and sequencing-are the engines for genomic interrogation and biomarker discovery, enabling precision treatment selection.
When grouped by cancer type, hematological cancers including leukemia, lymphoma, and multiple myeloma prioritize technologies that deliver single-cell resolution, cytogenetics, and rapid flow-based immunophenotyping. Conversely, solid tumors such as breast, colorectal, lung, and prostate cancers increasingly rely on multi-modality diagnostics that integrate imaging biomarkers with molecular profiles and tissue-based assays to guide localized and systemic therapies. From an end-user perspective, ambulatory care settings and hospitals demand turnkey solutions with rapid reporting and easy integration into electronic records, diagnostic laboratories focus on throughput, standardization, and quality controls, and research institutes-both academic and private-prioritize flexible platforms that support exploratory assays, method development, and mechanistic studies. These segmentation-driven contrasts inform technology roadmaps, service models, and evidence generation strategies for diagnostic stakeholders.
Regional dynamics and adoption pathways revealing how geopolitical, regulatory, and infrastructure factors drive differentiation in diagnostic uptake globally
Regional dynamics shape access, reimbursement frameworks, and adoption timelines for diagnostics technologies. In the Americas, investment in imaging infrastructure and molecular laboratories remains strong, driven by integrated health networks and a focus on precision oncology programs. Payor-driven reimbursement mechanisms and private sector procurement strategies influence the pace at which novel assays move into routine care, and cross-border manufacturing considerations affect supply chain resilience. Europe, the Middle East & Africa exhibits heterogeneous adoption patterns: Western European markets emphasize regulatory compliance, centralized reference testing, and robust laboratory accreditation, while emerging markets in the region weigh cost, scalability, and workforce capacity. Regulatory harmonization efforts in parts of the region may accelerate the adoption of standardized diagnostic workflows, but variability persists across national systems.
Asia-Pacific presents a rapidly evolving landscape where investment in high-throughput sequencing and digital pathology is accelerating, particularly in urban centers with strong research ecosystems. Public health priorities, population-scale screening initiatives, and localized manufacturing investments are key drivers. In many Asia-Pacific markets, expanding access to diagnostic services is catalyzing partnerships between hospitals, private laboratories, and research institutes, which in turn fuels demand for scalable, automated platforms. Across all regions, interoperability, data governance, and local regulatory frameworks remain critical considerations that shape deployment strategies and partnership models.
Competitive dynamics and capability strategies highlighting how integrated solutions, niche innovation, and strategic partnerships determine clinical traction
Competitive dynamics in the oncology diagnostics arena are defined by capability depth, portfolio breadth, and the ability to deliver integrated solutions that span instruments, assays, and data analytics. Leading players that combine robust reagent supply chains with instrument compatibility and scalable informatics architectures are positioned to capture complex clinical and research workflows. At the same time, niche innovators focused on specific modalities-such as ultra-sensitive sequencing, advanced multiplexed imaging, or next-generation flow cytometry-are reshaping value propositions by offering higher-resolution insights or workflow efficiencies that incumbents must respond to.
Strategic collaboration between manufacturers, diagnostic laboratories, and research organizations is increasingly common, enabling co-development of assays, real-world validation studies, and accelerated clinical translation. Service models that include managed testing, remote instrument monitoring, and data interpretation services add differentiation beyond hardware and reagents. Intellectual property around assay chemistries and bioinformatic pipelines continues to be a competitive moat, while agility in regulatory strategy, reimbursement engagement, and field support determines commercial traction. Companies that marry regulatory foresight with scalable manufacturing and strong clinical evidence generation will be best placed to lead adoption across diverse care settings.
Actionable recommendations for executives to align technology strategy, supply resilience, and evidence generation to accelerate clinical adoption and commercial success
Industry leaders should adopt a multi-pronged approach that aligns technological investment with operational resilience and evidence-based commercialization. Prioritize platform interoperability and open informatics standards to facilitate multi-modal data integration across imaging, molecular, and tissue-based assays, thereby enhancing clinical utility and easing adoption barriers. Invest in decentralized validation studies that demonstrate performance in ambulatory care, diagnostic laboratory, and hospital environments, ensuring that deployment models are tailored to the realities of each end-user type. Strengthen supplier diversification and inventory strategies to mitigate risks associated with trade policy shifts and component shortages, and evaluate localized manufacturing or contractual manufacturing partnerships where feasible.
From a commercial perspective, accelerate payer engagement to clarify reimbursement pathways and design outcomes studies that align with value-based payment frameworks. Cultivate collaborative partnerships with academic centers and private research institutes to co-create evidence and drive early adoption through key opinion leader endorsement. Finally, embed lifecycle support offerings-training, remote diagnostics, and data services-into commercial models to enhance customer retention and demonstrate total cost of ownership benefits. These actions will help organizations convert technological capability into sustained clinical and market advantage.
A transparent mixed-methods research approach combining primary clinician interviews, secondary technical validation, and scenario analysis to ensure robust insights
The research approach integrates a mixed-methods framework designed to validate findings across primary and secondary sources while ensuring transparency in analytical assumptions. Primary research included structured interviews with clinical leaders, laboratory directors, and procurement specialists across hospitals, diagnostic laboratories, ambulatory care settings, and academic and private research institutes to capture first‑hand insights on adoption drivers, operational constraints, and evidence needs. These qualitative inputs were triangulated with secondary research covering peer-reviewed literature, regulatory guidance documents, and publicly available technical validations to build a comprehensive understanding of modality-specific performance and use cases.
Analytical processes incorporated technology mapping to align instruments and assays with clinical workflows, segmentation analysis to discern end-user and cancer-type priorities, and scenario planning to assess implications of supply chain disruptions and policy shocks. Wherever possible, findings were cross-checked with multiple independent sources to ensure robustness, and caveats are noted where emerging data remain provisional. The methodology emphasizes reproducibility and clarity, enabling stakeholders to understand the provenance of conclusions and to request access to primary interview inventories or methodological appendices for verification and deeper inquiry.
A concise conclusion emphasizing pragmatic alignment of technological potential, supply resilience, and evidence programs to realize precision oncology benefits
In sum, oncology diagnostics stands at an inflection point where cross-disciplinary technologies and shifting policy environments jointly influence clinical pathways and commercial strategies. The most impactful innovations are those that deliver clinically actionable information while fitting within operational constraints across hospitals, laboratories, and ambulatory facilities. Technology adoption will be accelerated by demonstrable improvements in diagnostic confidence and downstream patient management, supported by rigorous evidence generation and streamlined regulatory engagements.
Stakeholders that prioritize data interoperability, supply chain resilience, and collaborative evidence programs will be best positioned to translate diagnostic innovation into improved patient outcomes and sustainable business models. While trade policy and regional heterogeneity introduce complexity, they also create opportunities for strategic localization and partnership. The conclusion emphasizes pragmatic alignment between technological possibility and implementation reality, encouraging decision-makers to integrate these insights into capital planning, clinical pathway redesign, and research collaborations to realize the promise of precision oncology diagnostics.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
184 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of artificial intelligence algorithms for early cancer detection and risk stratification
- 5.2. Adoption of liquid biopsy tests for minimally invasive monitoring of tumor dynamics and treatment response
- 5.3. Expansion of companion diagnostics for personalized oncology therapies driven by genomic profiling data
- 5.4. Implementation of multiomics approaches combining proteomics and metabolomics for comprehensive tumor profiling
- 5.5. Growth of decentralized point-of-care cancer screening platforms enabling remote patient access and early intervention
- 5.6. Regulatory approvals and reimbursement expansions accelerating access to next-generation sequencing in oncology diagnostics
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Cancer Diagnostics Market, by Technology
- 8.1. Flow Cytometry
- 8.1.1. Cell Sorting
- 8.1.2. Multiparameter Flow Cytometry
- 8.2. Imaging
- 8.2.1. Computed Tomography
- 8.2.2. Magnetic Resonance Imaging
- 8.2.3. Positron Emission Tomography
- 8.2.4. Ultrasound
- 8.3. Immunohistochemistry
- 8.3.1. Chromogenic
- 8.3.2. Fluorescent
- 8.4. In Situ Hybridization
- 8.5. Molecular Diagnostics
- 8.5.1. Microarray
- 8.5.2. Pcr
- 8.5.3. Sequencing
- 9. Cancer Diagnostics Market, by Cancer Type
- 9.1. Hematological Cancers
- 9.1.1. Leukemia
- 9.1.2. Lymphoma
- 9.1.3. Multiple Myeloma
- 9.2. Solid Tumors
- 9.2.1. Breast Cancer
- 9.2.2. Colorectal Cancer
- 9.2.3. Lung Cancer
- 9.2.4. Prostate Cancer
- 10. Cancer Diagnostics Market, by End User
- 10.1. Ambulatory Care
- 10.2. Diagnostic Laboratories
- 10.3. Hospitals
- 10.4. Research Institutes
- 10.4.1. Academic Institutes
- 10.4.2. Private Research Centers
- 11. Cancer Diagnostics Market, by Region
- 11.1. Americas
- 11.1.1. North America
- 11.1.2. Latin America
- 11.2. Europe, Middle East & Africa
- 11.2.1. Europe
- 11.2.2. Middle East
- 11.2.3. Africa
- 11.3. Asia-Pacific
- 12. Cancer Diagnostics Market, by Group
- 12.1. ASEAN
- 12.2. GCC
- 12.3. European Union
- 12.4. BRICS
- 12.5. G7
- 12.6. NATO
- 13. Cancer Diagnostics Market, by Country
- 13.1. United States
- 13.2. Canada
- 13.3. Mexico
- 13.4. Brazil
- 13.5. United Kingdom
- 13.6. Germany
- 13.7. France
- 13.8. Russia
- 13.9. Italy
- 13.10. Spain
- 13.11. China
- 13.12. India
- 13.13. Japan
- 13.14. Australia
- 13.15. South Korea
- 14. Competitive Landscape
- 14.1. Market Share Analysis, 2024
- 14.2. FPNV Positioning Matrix, 2024
- 14.3. Competitive Analysis
- 14.3.1. F. Hoffmann-La Roche Ltd
- 14.3.2. Abbott Laboratories
- 14.3.3. Thermo Fisher Scientific Inc.
- 14.3.4. Danaher Corporation
- 14.3.5. QIAGEN N.V.
- 14.3.6. Sysmex Corporation
- 14.3.7. Illumina, Inc.
- 14.3.8. bioMérieux SA
- 14.3.9. Siemens Healthineers AG
- 14.3.10. Agilent Technologies, Inc.
- 14.3.11. GE HealthCare Technologies Inc.
- 14.3.12. Hologic, Inc.
- 14.3.13. Becton, Dickinson and Company
- 14.3.14. Myriad Genetics, Inc.
- 14.3.15. DiaSorin S.p.A.
- 14.3.16. Fujifilm Corporation
- 14.3.17. Quest Diagnostics Incorporated
- 14.3.18. Danaher Corporation
- 14.3.19. Bio-Rad Laboratories, Inc.
- 14.3.20. PerkinElmer, Inc.
- 14.3.21. NeoGenomics Laboratories, Inc.
- 14.3.22. Canon Medical Systems Corporation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
